Carlyle in Talks To Buy Pharmaceutical Product Development Inc.

Private-equity Carlyle Group is in talks to acquire Pharmaceutical Product Development Inc., media reports said Monday, quoting people familiar with the matter.

Carlyle Group edged out other private-equities such as Blackstone Group, KKR & Co., and Hellman & Friedman that evinced interest in the clinical research company. Most bids were between $33 and $38 a share, or as much as $4.3 billion.
Carlyle is also said to be in talks with other private-equity firms regarding involvement in the acquisition of North Carolina-based Pharmaceutical Product Development Inc.

For Carlyle, the purchase of Pharmaceutical Product Development Inc. would be its largest since announcing the $3.9 billion wrap-up of CommScope Inc. in October. Separately, Carlyle today said it will sell Insight Communications Co. to Time Warner Cable Inc. for about $3.0 billion.

Pharmaceutical Product Development Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. Last month, the company said its second quarter profit surged to $46.51 million or $0.41 per share from $20.98 million or $0.18 per share last year. Quarterly sales jumped to $407.70 million from $369.92 million.

 

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.